Stocks and Investing
Stocks and Investing
Thu, October 3, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Andrew Fein Reiterated (ABOS) at Strong Buy and Held Target at $15 on, Oct 3rd, 2024
Andrew Fein of HC Wainwright & Co., Reiterated "Acumen Pharmaceuticals, Inc." (ABOS) at Strong Buy and Held Target at $15 on, Oct 3rd, 2024.
Andrew has made no other calls on ABOS in the last 4 months.
There are 2 other peers that have a rating on ABOS. Out of the 2 peers that are also analyzing ABOS, 0 agree with Andrew's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Andrew
- Colin Bristow of "UBS" Maintained at Strong Buy with Decreased Target to $6 on, Thursday, August 15th, 2024
- David Hoang of "Citigroup" Initiated at Strong Buy and Held Target at $7 on, Thursday, July 25th, 2024
Contributing Sources